Extract from the Register of European Patents

EP About this file: EP2797959

EP2797959 - ASPARTYL-TRNA SYNTHETASE-FC CONJUGATES [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  01.11.2019
Database last updated on 28.03.2026
FormerExamination is in progress
Status updated on  16.12.2016
Most recent event   Tooltip01.11.2019Application deemed to be withdrawnpublished on 04.12.2019  [2019/49]
Applicant(s)For all designated states
Atyr Pharma, Inc.
3545 John Hopkins Court, Suite No. 250
San Diego, CA 92121 / US
[2014/45]
Inventor(s)01 / BUECHLER, Ying Ji
1343 Cassins Street
Carlsbad California 92011 / US
02 / WU, Chi-Fang
2649 Villas Way
San Diego California 92108 / US
03 / ADAMS, Ryan A.
1260 Diamond Street
San Diego California 92109 / US
04 / WATKINS, Jeffry D.
3442 Fortuna Ranch Road
Encinitas California 92024 / US
05 / MENDLEIN, John D.
1550 Neptune Avenue
Encinitas California 92024 / US
 [2014/45]
Representative(s)Høiberg P/S
Adelgade 12
1304 Copenhagen K / DK
[N/P]
Former [2014/45]Høiberg A/S
St. Kongensgade 59 A
1264 Copenhagen K / DK
Application number, filing date12867497.527.12.2012
WO2012US71762
Priority number, dateUS201161581550P29.12.2011         Original published format: US 201161581550 P
[2014/45]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2013115926
Date:08.08.2013
Language:EN
[2013/32]
Type: A2 Application without search report 
No.:EP2797959
Date:05.11.2014
Language:EN
The application published by WIPO in one of the EPO official languages on 08.08.2013 takes the place of the publication of the European patent application.
[2014/45]
Search report(s)International search report - published on:KR31.10.2013
(Supplementary) European search report - dispatched on:EP24.07.2015
ClassificationIPC:C07K19/00, A61K38/16, C12N15/62, A61P35/00, A61K38/00, C12N9/00, C07K16/00
[2015/22]
CPC:
C12N9/93 (EP,US); A61P29/00 (EP); A61P35/00 (EP);
A61P37/02 (EP); A61P43/00 (EP); C07K16/00 (US);
C12Y601/01012 (EP,US); A61K38/00 (EP,US); C07K2319/02 (EP,US);
C07K2319/21 (EP,US); C07K2319/30 (EP,US); C07K2319/50 (EP,US);
C12Y601/01002 (EP,US); Y02A50/30 (EP,US) (-)
Former IPC [2014/45]C07K19/00, A61K38/16, C12N15/62, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2014/45]
TitleGerman:ASPARTYL-TRNA-SYNTHETASE-FC-KONJUGATE[2014/45]
English:ASPARTYL-TRNA SYNTHETASE-FC CONJUGATES[2014/45]
French:CONJUGUÉS ASPARTYL-ARNT SYNTHÉTASE-FC[2014/45]
Entry into regional phase29.07.2014National basic fee paid 
29.07.2014Search fee paid 
29.07.2014Designation fee(s) paid 
29.07.2014Examination fee paid 
Examination procedure29.07.2014Examination requested  [2014/45]
17.02.2016Amendment by applicant (claims and/or description)
16.12.2016Despatch of a communication from the examining division (Time limit: M06)
02.10.2017Reply to a communication from the examining division
14.05.2018Despatch of a communication from the examining division (Time limit: M04)
06.09.2018Reply to a communication from the examining division
02.07.2019Application deemed to be withdrawn, date of legal effect  [2019/49]
29.07.2019Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [2019/49]
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  16.12.2016
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
02.10.2017Request for further processing filed
02.10.2017Full payment received (date of receipt of payment)
Request granted
16.10.2017Decision despatched
Fees paidRenewal fee
17.12.2014Renewal fee patent year 03
28.12.2015Renewal fee patent year 04
27.12.2016Renewal fee patent year 05
27.12.2017Renewal fee patent year 06
Penalty fee
Additional fee for renewal fee
31.12.201807   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court
See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[XI] WO2010120509  (ATYR PHARMA INC et al.) [X] 1,7,8,11-15 * abstract * * page 1, paragraph 3 * * page 3, paragraph 3 - page 7, paragraph 4 * * page 33, paragraph 1 * * page 35, paragraph 4 * * page 99 - page 112 * * claims 1-6,9,10,29-37 * * sequence 1 *[I] 5,6,9,10
 [XP] WO2012009289  (ATYR PHARMA INC et al.) [XP] 1,7,8,11-15 * abstract * * paragraphs [0003] , [0009] , [0118] , [0166] , [0408] , [0433] * * tables 1, 3 * * sequences 12, 50 *
 [Y] US2003166241  (FAMODU OMOLAYO O et al.) [Y] 1,5-15 * abstract * * paragraphs [0006] - [0010] * * sequence 25 *
 [E] WO2013086216  (ATYR PHARMA INC et al.) [E] 1,4-15 * abstract * * page 1, paragraph 3 * * page 4, paragraph 5 * * page 5, paragraph 6 * * page 7, paragraph 2 - page 8, paragraph 3 * * page 64, paragraph 4 * * sequences 4, 89 *
 [Y]   DUMONT JENNIFER A ET AL: "MONOMERIC FC FUSIONS: IMPACT ON PHARMACOKINETIC AND BIOLOGICAL ACTIVITY OF PROTEIN THERAPEUTICS", BIODRUGS: CLINICAL IMMUNOTHERAPEUTICS, BIOPHARMACEUTICALS AND GENE THERAPY, ADIS INTERNATIONAL, FR, vol. 20, no. 3, 1 January 2006 (2006-01-01), pages 151 - 160, XP009082835, ISSN: 1173-8804, DOI: 10.2165/00063030-200620030-00002 [Y] 1,5-15 * the whole document *

DOI:   http://dx.doi.org/10.2165/00063030-200620030-00002
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.